Valuation: Belite Bio, Inc

Capitalization 597.85Cr 507.33Cr 464.62Cr 438.08Cr 817.1Cr 57TCr 823.66Cr 5.51TCr 2.15TCr 27TCr 2.24TCr 2.2TCr 94TCr P/E ratio 2026 *
-70.4x
P/E ratio 2027 * 204x
Enterprise value 542.23Cr 460.13Cr 421.4Cr 397.32Cr 741.08Cr 52TCr 747.03Cr 5TCr 1.95TCr 25TCr 2.03TCr 1.99TCr 85TCr EV / Sales 2026 *
211x
EV / Sales 2027 * 29.7x
Free-Float
55.91%
Yield 2026 *
-
Yield 2027 * -
1 day-1.88%
1 week-1.64%
Current month-4.52%
1 month-12.03%
3 months-13.19%
6 months+43.69%
Current year-4.99%
1 week 147.84
Extreme 147.84
158.64
1 month 147.84
Extreme 147.84
179
Current year 146.06
Extreme 146.06
200
1 year 56.1
Extreme 56.1
200
3 years 11
Extreme 11
200
5 years 8.8
Extreme 8.8
200
10 years 8.8
Extreme 8.8
200
Manager TitleAgeSince
Chief Executive Officer 48 27/03/2018
Director of Finance/CFO 42 01/11/2020
Chief Tech/Sci/R&D Officer 58 01/09/2024
Director TitleAgeSince
Director/Board Member 42 01/11/2020
Chairman 48 27/03/2018
Director/Board Member 40 01/11/2021
Change 5d. change 1-year change 3-years change Capi.($)
-1.88%-1.64%+148.72%+466.84% 597.85Cr
+3.04%+0.99%+39.35%+87.67% 5.07TCr
+1.80%-0.76%+84.08%+60.38% 4.86TCr
-0.83%-6.05%+0.61%-9.01% 2.36TCr
+2.51%-25.80%+59.63%+448.23% 2.25TCr
+3.02%+0.47%+46.24%-26.17% 1.75TCr
+1.07%-2.84%+25.78%-42.17% 1.61TCr
-0.38%+2.11%+64.15%+206.70% 1.54TCr
+3.21%+9.89%-22.12%+869.35% 1.45TCr
+2.54%+1.09%+50.52% - 1.34TCr
Average +1.40%-3.04%+49.70%+229.09% 2.28TCr
Weighted average by Cap. +1.79%-3.03%+47.74%+161.53%

Financials

2026 *2027 *
Net sales 2.57Cr 2.18Cr 2Cr 1.88Cr 3.51Cr 244.99Cr 3.54Cr 24Cr 9.25Cr 116.68Cr 9.65Cr 9.45Cr 403.78Cr 18Cr 16Cr 14Cr 13Cr 25Cr 1.74TCr 25Cr 168.64Cr 66Cr 830.25Cr 69Cr 67Cr 2.87TCr
Net income -7.94Cr -6.74Cr -6.17Cr -5.82Cr -11Cr -756.72Cr -11Cr -73Cr -29Cr -360.4Cr -30Cr -29Cr -1.25TCr 2.24Cr 1.9Cr 1.74Cr 1.64Cr 3.06Cr 213.58Cr 3.09Cr 21Cr 8.06Cr 101.72Cr 8.41Cr 8.23Cr 352.01Cr
Net Debt -56Cr -47Cr -43Cr -41Cr -76Cr -5.3TCr -77Cr -512.65Cr -200.1Cr -2.52TCr -208.7Cr -204.31Cr -8.73TCr -55Cr -47Cr -43Cr -40Cr -76Cr -5.26TCr -76Cr -509.15Cr -198.73Cr -2.51TCr -207.27Cr -202.92Cr -8.67TCr
Logo Belite Bio, Inc
Belite Bio, Inc is a clinical-stage biopharmaceutical drug development company. The Company is focused on advancing novel therapeutics targeting retinal degenerative eye disease, such as Geographic Atrophy (GA), age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1), both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout. Its lead product candidate, Tinlarebant, is an oral daily treatment for STGD1 and GA patients. In STGD1, it is developing Tinlarebant as a once-a-day tablet treatment to target Retinol binding protein 4 (RBP4) by disrupting vitamin A (retinol) binding to RBP4, which leads to reduced delivery of retinol to the eye and reduced accumulation of toxic vitamin A by-products. Its product candidate also includes LBS-009, an anti-RBP4 oral therapy targeting liver disease, including NAFLD, NASH, and T2D.
Employees
41
Date Price Change Volume
11/26/11 151.97 $ -1.88% 67,289
08/26/08 154.88 $ -0.72% 59,995
07/26/07 156.00 $ -0.13% 1,36,694
06/26/06 156.21 $ +1.19% 1,73,941
05/26/05 154.38 $ -0.08% 88,473
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
151.97USD
Average target price
211.50USD
Spread / Average Target
+39.17%

Quarterly revenue - Rate of surprise